tbuckley/cabot-search huggingface dataset:
EP01.05-006 Influenza Season Influence on Incidence and Outcome of Nodules in the NELSON Trial
Authors: H.L. Lancaster, M.A. Heuvelmans, G.H. de Bock, F.A.A. Mohamed Hoesein, K. Nackaerts, J.E. Walter, R. Vliegenthart, M. Oudkerk
Journal: Journal of Thoracic Oncology (2022)
EP03.01-012 Characterization of Lung Cancer in Patients With High Familial Aggregation of Cancer: Preliminary Data From the SCAN Study
Authors: J.C. Laguna, J. Torres-Jiménez, E. Auclin, L. Gonzalez-Aguado, V. Albarrán-Artahona, B. Pastor, T. Gorría, L. Moreno, M. Potrony, R. Reyes, P. Blasco, D. Martínez, N. Viñolas, L. Gaba, B. Adamo, A. Arcocha, J.A. Puig-Butillé, A. Prat, C. Teixidó, N. Reguart, L. Mezquita
Journal: Journal of Thoracic Oncology (2022)
P1.14-05 TROP2 Expression and SN38 Antitumor Activity in Malignant Pleural Mesothelioma Cells
Authors: L. Hegedüs, Ö. Okumus, F. Mairinger, T. Plönes, S. Reuter, M. Schuler, D. Theegarten, Á. Bánkfalvi, C. Aigner, B. Hegedüs
Journal: Journal of Thoracic Oncology (2022)
EP06.01-010 Clinical Outcomes after Hypo Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer During The Covid-19 Pandemic In Morocco
Authors: M. cherkaoui, S. Guendaoui, T. Chekrine, M. Bourhafour, Z. Bouchbika, J. hassan, N. Tawfiq, S. Sahraoui
Journal: Journal of Thoracic Oncology (2022)
MA03.03 Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage IA Non-small Cell Lung Cancer: A Prospective Cohort Study
Authors: J. Lee, H.Y. Lee, Y.J. Jeon, S. Shin, J.H. CHo, Y.S. Choi, J. Kim, J.I. Zo, Y.M. Shim, H.K. Kim
Journal: Journal of Thoracic Oncology (2022)
EP04.02-001 Sex as a Potential Independent Prognostic Factor in Non-Small Cell Lung Cancer Survival
Authors: C. Ford-Sahibzada, M. Dean, C. Peters, D. Brenner, A. Gibson, A. D'Silva, A. Elegbede, R. Tudor, G.D. Bebb, W. Cheung
Journal: Journal of Thoracic Oncology (2022)
EP04.01-015 Lung Cancer after Solid Organ Transplantation - A Claims Data Analysis
Authors: J. Walter, J. Kovàcs, D. Munker, L. Sellmer, T. Kauke, J. Behr, J. Barton, N. Kneidinger, C. Schneider, A. Tufman
Journal: Journal of Thoracic Oncology (2022)
P2.12-04 The Role of Serum Proteomic Signature in Predicting Survival in PD-L1 Low Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor (ICI)
Authors: L. Kim, Y. Oh, S.M. Yoon, J.H. Park, Y.K. Chae
Journal: Journal of Thoracic Oncology (2022)
EP02.03-021 Uncertain Resection for Localized cN0M0 Non Small Cell-Lung Cancer: The Crucial Prognosis of Suboptimal Lymph Node Assessment
Authors: R. Vergé, A. Rouch, C. Renaud, L. Mazzoni, M. Cazaux, P. Rabinel, L. Brouchet
Journal: Journal of Thoracic Oncology (2022)
EP07.01-012 Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma
Authors: M. Jakopovic, F. Seiwerth, L. Bitar, L. Ljubicic, O. Maletic, S. Karabatic, M. Samarzija
Journal: Journal of Thoracic Oncology (2022)
The Association of Borderline Hypertension With Target Organ Changes and Higher Coronary Risk
Authors: Stevo Julius
Journal: JAMA (1990)

The Tecumseh project investigates the evolution of hypertension in a healthy population. Of 946 subjects aged 18 through 38 years, 124 had clinic blood pressure readings higher than 140/90 mm Hg (the mean for borderline hypertensive subjects was 130/94 mm Hg). Compared with normotensive subjects, borderline hypertensive subjects had higher home blood pressures (mean, 12/7 mm Hg higher). Their childhood and postpubertal blood pressures were elevated (6/4 mm Hg higher than normal at age 6 years and 12/7 mm Hg higher than normal at age 21 years), and hypertensive target organ changes were detected. Borderline hypertensive subjects also had elevated minimal forearm resistance (0.22 U higher than normal), decreased stroke index (1.8 mL/m<sup>2</sup>lower than normal), and impaired ventricular diastolic relaxation (mitral Doppler peak early diastolic blood flow [E] to peak late diastolic blood flow [A] ratio 0.13 lower than normal). Borderline hypertensive subjects had significant abnormalities in other coronary risk factors (cholesterol levels were 0.39 mmol/L higher, triglyceride levels were 0.45 mmol/L higher, high-density lipoprotein levels were 0.08 mmol/L lower, insulin levels were 38 pmol/L higher, and 16.5% more of them were overweight). Borderline hypertension is neither transient nor innocuous. Its association with other predictors of atherosclerosis calls for clinical attention. (<i>JAMA</i>. 1990;264:354-358)
The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management
Authors: Roger S. McIntyre, Martin Alda, Ross J. Baldessarini, Michael Bauer, Michael Berk, Christoph U. Correll, Andrea Fagiolini, Kostas Fountoulakis, Mark A. Frye, Heinz Grunze, Lars V. Kessing, David J. Miklowitz, Gordon Parker, Robert M. Post, Alan C. Swann, Trisha Suppes, Eduard Vieta, Allan Young, Mario Maj
Journal: World Psychiatry (2022)

Bipolar disorder is heterogeneous in phenomenology, illness trajectory, and response to treatment. Despite evidence for the efficacy of multimodal-ity interventions, the majority of persons affected by this disorder do not achieve and sustain full syndromal recovery. It is eagerly anticipated that combining datasets across various information sources (e.g., hierarchical "multi-omic" measures, electronic health records), analyzed using advanced computational methods (e.g., machine learning), will inform future diagnosis and treatment selection. In the interim, identifying clinically meaningful subgroups of persons with the disorder having differential response to specific treatments at point-of-care is an empirical priority. This paper endeavours to synthesize salient domains in the clinical characterization of the adult patient with bipolar disorder, with the overarching aim to improve health outcomes by informing patient management and treatment considerations. Extant data indicate that characterizing select domains in bipolar disorder provides actionable information and guides shared decision making. For example, it is robustly established that the presence of mixed features - especially during depressive episodes - and of physical and psychiatric comorbidities informs illness trajectory, response to treatment, and suicide risk. In addition, early environmental exposures (e.g., sexual and physical abuse, emotional neglect) are highly associated with more complicated illness presentations, inviting the need for developmentally-oriented and integrated treatment approaches. There have been significant advances in validating subtypes of bipolar disorder (e.g., bipolar I vs. II disorder), particularly in regard to pharmacological interventions. As with other severe mental disorders, social functioning, interpersonal/family relationships and internalized stigma are domains highly relevant to relapse risk, health outcomes, and quality of life. The elevated standardized mortality ratio for completed suicide and suicidal behaviour in bipolar disorder invites the need for characterization of this domain in all patients. The framework of this paper is to describe all the above salient domains, providing a synthesis of extant literature and recommendations for decision support tools and clinical metrics that can be implemented at point-of-care.
MA13.07 TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Authors: B. Levy, L. Paz-Ares, O. Rixe, W.-C. Su, T.-Y. Yang, A. Tolcher, Y. Lou, Y. Zenke, P. Savvides, E. Felip, M. Domine, K. Leventakos, M.P. Pulla, M. Koczywas, A. Horiike, S. Rawat, X. Wu, P. Basak, M. Chisamore, Y. Goto
Journal: Journal of Thoracic Oncology (2022)
EP02.01-015 Computer-Aided Volumetry by Multidetector Computed Tomography is Efficient for Prognostic Prediction of Early-Stage Solid Lung Cancers
Authors: T. Kato, S. Iwano, R. Katsuya, S. Okado, T. Ito, K. Sato, K. Nakanishi, Y. Kadomatsu, H. Ueno, N. Ozeki, S. Nakamura, K. Fukumoto, T.F. Chen-Yoshikawa
Journal: Journal of Thoracic Oncology (2022)
Psychiatric diagnosis and treatment in the 21st century: paradigm shifts versus incremental integration
Authors: Dan J. Stein, Steven J. Shoptaw, Daniel V. Vigo, Crick Lund, Pim Cuijpers, Jason Bantjes, Norman Sartorius, Mario Maj
Journal: World Psychiatry (2022)

Psychiatry has always been characterized by a range of different models of and approaches to mental disorder, which have sometimes brought progress in clinical practice, but have often also been accompanied by critique from within and without the field. Psychiatric nosology has been a particular focus of debate in recent decades; successive editions of the DSM and ICD have strongly influenced both psychiatric practice and research, but have also led to assertions that psychiatry is in crisis, and to advocacy for entirely new paradigms for diagnosis and assessment. When thinking about etiology, many researchers currently refer to a biopsychosocial model, but this approach has received significant critique, being considered by some observers overly eclectic and vague. Despite the development of a range of evidence-based pharmacotherapies and psychotherapies, current evidence points to both a treatment gap and a research-practice gap in mental health. In this paper, after considering current clinical practice, we discuss some proposed novel perspectives that have recently achieved particular prominence and may significantly impact psychiatric practice and research in the future: clinical neuroscience and personalized pharmacotherapy; novel statistical approaches to psychiatric nosology, assessment and research; deinstitutionalization and community mental health care; the scale-up of evidence-based psychotherapy; digital phenotyping and digital therapies; and global mental health and task-sharing approaches. We consider the extent to which proposed transitions from current practices to novel approaches reflect hype or hope. Our review indicates that each of the novel perspectives contributes important insights that allow hope for the future, but also that each provides only a partial view, and that any promise of a paradigm shift for the field is not well grounded. We conclude that there have been crucial advances in psychiatric diagnosis and treatment in recent decades; that, despite this important progress, there is considerable need for further improvements in assessment and intervention; and that such improvements will likely not be achieved by any specific paradigm shifts in psychiatric practice and research, but rather by incremental progress and iterative integration.
Use of low‐dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator‐controlled cohort study
Authors: Mikkel Højlund, Kjeld Andersen, Martin T. Ernst, Christoph U. Correll, Jesper Hallas
Journal: World Psychiatry (2022)

At standard doses used for schizophrenia or bipolar disorder, quetiapine has been associated with weight gain and increased levels of triglycerides, to-tal cholesterol and low-density lipoprotein (LDL) cholesterol, which are risk factors for cardiovascular morbidity and mortality. However, this drug is also commonly used off-label at low doses for anxiolytic or hypnotic purposes, and its cardiovascular safety at these doses is unknown. We aimed to assess the risk of major adverse cardiovascular events with use of low-dose quetiapine compared to use of Z-drug hypnotics in a nationwide, active comparator-controlled cohort study. The cohort included new users of either drugs in Denmark from 2003 to 2017, aged 18-85 years, without history of ischemic stroke, myocardial infarction, cancer, and severe mental illness. The main outcome was the occurrence of major adverse cardiovascular events, defined as non-fatal myocardial infarction or ischemic stroke, or death from cardiovascular causes. Selective serotonin reuptake inhibitors (SSRIs) were used as an alternative comparator in sensitivity analyses. Altogether, we compared 60,566 low-dose quetiapine users with 454,567 Z-drug users, followed for 890,198 person-years in intent-to-treat analysis, and 330,334 person-years in as-treated analysis. In intention-to-treat analysis, low-dose quetiapine was associated with an increased risk of major adverse cardiovascular events (adjusted hazard ratio, aHR=1.13, 95% CI: 1.02-1.24, p=0.014) and cardiovascular death (aHR=1.26, 95% CI: 1.11-1.43, p<0.001). In as-treated analysis, continuous low-dose quetiapine use was associated with increased risk of major adverse cardiovascular events (aHR=1.52, 95% CI: 1.35-1.70, p<0.001), non-fatal ischemic stroke (aHR=1.37, 95% CI: 1.13-1.68, p=0.002) and cardiovascular death (aHR=1.90, 95% CI: 1.64-2.19, p<0.001). The risk of major adverse cardiovascular events was greater in women (aHR=1.28, p=0.02) and those aged ≥65 years at initiation (aHR=1.24, p<0.001). Compared to SSRIs, low-dose quetiapine use was associated with an increased risk of major adverse cardiovascular events (aHR=1.42, p<0.001), non-fatal ischemic stroke (aHR=1.27, p=0.0028) and cardiovascular death (aHR=1.72, p<0.001). So, we conclude that the use of low-dose quetiapine is associated with an increased risk of major adverse cardiovascular events, especially in women and the elderly. On the basis of these findings, we suggest that use of off-label low-dose quetiapine for sedative or hypnotic purposes should be discouraged.
Housing and Cancer Care and Outcomes: A Systematic Review
Authors: Qinjin Fan, Leticia Nogueira, K Robin Yabroff, S M Qasim Hussaini, Craig E Pollack
Journal: JNCI Journal of the National Cancer Institute (2022)

Access to stable and affordable housing is an important social determinant of health in the United States. However, research addressing housing and cancer care, diagnosis, and outcomes has not been synthesized.
Liposomal formulations for treating lysosomal storage disorders
Authors: Judit Tomsen-Melero, Josep Merlo-Mas, Aida Carreño, Santi Sala, Alba Córdoba, Jaume Veciana, Elisabet González-Mira, Nora Ventosa
Journal: Advanced Drug Delivery Reviews (2022)

Lysosomal storage disorders (LSD) are a group of rare life-threatening diseases caused by a lysosomal dysfunction, usually due to the lack of a single enzyme required for the metabolism of macromolecules, which leads to a lysosomal accumulation of specific substrates, resulting in severe disease manifestations and early death. There is currently no definitive cure for LSD, and despite the approval of certain therapies, their effectiveness is limited. Therefore, an appropriate nanocarrier could help improve the efficacy of some of these therapies. Liposomes show excellent properties as drug carriers, because they can entrap active therapeutic compounds offering protection, biocompatibility, and selectivity. Here, we discuss the potential of liposomes for LSD treatment and conduct a detailed analysis of promising liposomal formulations still in the preclinical development stage from various perspectives, including treatment strategy, manufacturing, characterization, and future directions for implementing liposomal formulations for LSD.
Evaluation of Risk Factors for Postbooster Omicron COVID-19 Deaths in England
Authors: Vahé Nafilyan, Isobel L. Ward, Chris Robertson, Aziz Sheikh
Journal: JAMA Network Open (2022)

This cohort study of adults in England evaluates the association of sociodemographic and clinical risk factors with death from COVID-19 among individuals who completed primary vaccination and received a messenger RNA (mRNA) booster.
COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022
Authors: Fiona P. Havers, Huong Pham, Christopher A. Taylor, Michael Whitaker, Kadam Patel, Onika Anglin, Anita K. Kambhampati, Jennifer Milucky, Elizabeth Zell, Heidi L. Moline, Shua J. Chai, Pam Daily Kirley, Nisha B. Alden, Isaac Armistead, Kimberly Yousey-Hindes, James Meek, Kyle P. Openo, Evan J. Anderson, Libby Reeg, Alexander Kohrman, Ruth Lynfield, Kathryn Como-Sabetti, Elizabeth M. Davis, Cory Cline, Alison Muse, Grant Barney, Sophrena Bushey, Christina B. Felsen, Laurie M. Billing, Eli Shiltz, Melissa Sutton, Nasreen Abdullah, H. Keipp Talbot, William Schaffner, Mary Hill, Andrea George, Aron J. Hall, Stephanie R. Bialek, Neil C. Murthy, Bhavini Patel Murthy, Meredith McMorrow
Journal: JAMA Internal Medicine (2022)

Understanding risk factors for hospitalization in vaccinated persons and the association of COVID-19 vaccines with hospitalization rates is critical for public health efforts to control COVID-19.
Trends in Postoperative Intensity-Modulated Radiation Therapy Use and Its Association With Survival Among Patients With Incompletely Resected Non–Small Cell Lung Cancer
Authors: Brian Yu, Sung Jun Ma, Olivia Waldman, Cynthia Dunne-Jaffe, Udit Chatterjee, Lauren Turecki, Jasmin Gill, Keerti Yendamuri, Austin Iovoli, Mark Farrugia, Anurag K. Singh
Journal: JAMA Network Open (2022)

<h3>Importance</h3> National guidelines allow consideration of postoperative radiation therapy (PORT) among patients with incompletely resected non–small cell lung cancer (NSCLC). However, there is a paucity of prospective data because recently completed trials excluded patients with positive surgical margins. In addition, unlike for locally advanced NSCLC, the role of intensity-modulated radiation therapy (IMRT) for PORT remains unclear. <h3>Objective</h3> To evaluate trends of IMRT use for PORT in the US and the association of IMRT with survival outcomes among patients with incompletely resected NSCLC. <h3>Design, Setting, and Participants</h3> This retrospective cohort study used data from the National Cancer Database for patients diagnosed between January 2004 and December 2019 with incompletely resected NSCLC who underwent upfront surgery with positive surgical margins followed by PORT. <h3>Exposures</h3> IMRT vs 3D conformal radiation therapy (3DCRT) for PORT. <h3>Main Outcomes and Measures</h3> The main outcome was overall survival. Multivariable Cox proportional hazards regression assessed the association of IMRT vs 3DCRT with overall survival. Multivariable logistic regression identified variables associated with IMRT. Propensity score matching (1:1) was performed based on variables of interest. <h3>Results</h3> A total of 4483 patients (2439 men [54.4%]; median age, 67 years [IQR, 60-73 years]) were included in the analysis. Of those, 2116 (47.2%) underwent 3DCRT and 2367 (52.8%) underwent IMRT. Median follow-up was 48.5 months (IQR, 31.1-77.2 months). The proportion of patients who underwent IMRT increased from 14.3% (13 of 91 patients) in 2004 to 70.7% (33 of 471 patients) in 2019 (<i>P</i> &lt; .001). IMRT was associated with improved overall survival compared with 3DCRT (adjusted hazard ratio, 0.84; 95% CI, 0.78-0.91;<i>P</i> &lt; .001). Similar findings were observed for 1463 propensity score–matched pairs; IMRT was associated with improved 5-year overall survival compared with 3DCRT (37.3% vs 32.2%; hazard ratio, 0.88; 95% CI, 0.80-0.96;<i>P</i> = .003). IMRT use was associated with receipt of treatment at an academic facility (adjusted odds ratio [aOR], 1.15; 95% CI, 1.00-1.33;<i>P</i> = .049), having T4 stage tumors (aOR, 1.50; 95% CI, 1.13-1.99;<i>P</i> = .005) or N2 or N3 stage tumors (aOR, 1.25; 95% CI, 1.04-1.51;<i>P</i> = .02), and receipt of pneumonectomy (aOR, 1.35; 95% CI, 1.02-1.80;<i>P</i> = .04). <h3>Conclusion and Relevance</h3> This cohort study found that use of IMRT for PORT among patients with incompletely resected NSCLC increased in the US from 2004 to 2019 and was associated with improved survival compared with 3DCRT. Further studies are warranted to investigate the role of different radiation therapy techniques for PORT.
Protecting the Privacy of Individuals Seeking Abortion
Authors: Mitchell H. Katz
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Authors: Joana Vidal, Maria Concepción Fernández-Rodríguez, David Casadevall, Pilar García-Alfonso, David Páez, Marta Guix, Vicente Alonso, Maria Teresa Cano, Cristina Santos, Gema Durán, Elena Elez, José Luís Manzano, Rocío Garcia-Carbonero, Reyes Ferreiro, Ferran Losa, Estela Pineda, Javier Sastre, Fernando Rivera, Beatriz Bellosillo, Josep Tabernero, Enrique Aranda, Ramon Salazar, Clara Montagut
Journal: Clinical Cancer Research (2022)

Chemotherapy plus anti-EGFR is standard first-line therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC), but biomarkers of early response are clinically needed. We aimed to define the utility of ctDNA to assess early response in patients with mCRC receiving first-line anti-EGFR therapy.Prospective multicentric study of tissue patients with RAS wt mCRC treated with first-line chemotherapy plus cetuximab undergoing sequential liquid biopsies. Baseline and early (C3) ctDNA were analyzed by NGS. Trunk mutations were assessed as surrogate marker of total tumor burden. RAS/BRAF/MEK/EGFR-ECD were considered mutations of resistance. ctDNA results were correlated with clinical outcome.One hundred patients were included. ctDNA was detected in 72% of patients at baseline and 34% at C3. Decrease in ctDNA trunk mutations correlated with progression-free survival (PFS; HR, 0.23; P = 0.001). RAS/BRAF were the only resistant mutations detected at C3. An increase in the relative fraction of RAS/BRAF at C3 was followed by an expansion of the RAS clone until PD, and was associated with shorter PFS (HR, 10.5; P < 0.001). The best predictor of response was the combined analysis of trunk and resistant mutations at C3. Accordingly, patients with "early molecular response" (decrease in trunk and decrease in resistant mutations) had better response (77.5% vs. 25%, P = 0.008) and longer PFS (HR, 0.18; P < 0.001) compared with patients with "early molecular progression" (increase in trunk and/or increase in resistant mutations).ctDNA detects early molecular response and predicts benefit to chemotherapy plus cetuximab. A comprehensive NGS-based approach is recommended to integrate information on total disease burden and resistant mutations. See related commentary by Eluri et al., p. 302.
Changes in Opioid Prescriptions and Potential Misuse and Substance Use Disorders Among Childhood Cancer Survivors Following the 2016 Opioid Prescribing Guideline
Authors: Xin Hu, Katharine E. Brock, Karen E. Effinger, Bo Zhang, Ilana Graetz, Joseph Lipscomb, Xu Ji
Journal: JAMA Oncology (2022)

The Centers for Disease Control and Prevention (CDC) released an opioid-prescribing guideline in March 2016. Little is known about the guideline's potential effects on childhood cancer survivors, a population at high risk for pain.